Quidelortho (QDEL) Stock
Diagnostics company with recurring test kit and instrument sales. Here's the price, business snapshot, and what's worth knowing about Quidelortho in August 2026.
QuidelOrtho (ticker QDEL) is a diagnostics company that develops, manufactures and sells rapid point‑of‑care tests, laboratory immunoassays and related instruments. With a market capitalisation near $2.03bn, the business generates revenue from one‑off instrument placements and recurring test kit and reagent sales across infectious disease, cardiometabolic and women’s health markets. Investors should note the company’s exposure to public‑health cycles — demand can spike in pandemics and recede afterwards — as well as regulatory approvals, reimbursement dynamics and competition from other diagnostics firms. Recent integration of acquisitions and manufacturing scale‑up are potential growth levers but introduce execution risk. Financial metrics such as margins, cash flow and debt levels are important to monitor. This is general educational information, not personalised investment advice; values can fall as well as rise and prospective investors should assess their objectives and seek professional guidance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding QuidelOrtho's stock with a target price of $39.31, indicating potential growth.
Financial Health
QuidelOrtho is performing well with solid revenue and profit margins, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Diagnostics revenue drivers
Recurring reagent sales and instrument placements underpin revenue, though demand can be cyclical and influenced by public‑health events.
Global market exposure
Products serve hospitals and labs worldwide; regulatory approvals and reimbursement affect adoption and geographic expansion carries execution risk.
Product pipeline focus
New assays and automation could bolster growth and margins, but launch success and regulatory review remain uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
